Clinical Breakthrough in Targeted Protein Degradation:Reflections on the Approval of ARV-471OA
On May 1,2026,the US Food and Drug Administration approved vepdegestrant(ARV-471;Veppanu),developed by Arvinas in partnership with Pfizer,for the treatment of ESR1-mutated,ER-positive/HER2-negative advanced or metastatic breast cancer[1].As the first PROTAC(proteolysis-targeting chimera)drug to reach the market,ARV-471 represents the culmination of more than two decades of scientific develop-ment,translating the concept of targeted protein degradation from academic laboratories into a clinically viable therapeutic modality.Its approval establishes a critical regulatory and commercial precedent for the broader class of degraders now advancing through pharmaceutical pipelines(Figure 1).
Yu Rao
MOE Key Laboratory of Protein Sciences,School of Pharmaceutical Sciences,MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology,State Key Laboratory of Molecular Oncology,Tsinghua University,Beijing,China Beijing Key Laboratory of Targeted Protein Degradation and Molecular Glue Therapeutics,Tsinghua University,Beijing,China
医药卫生
breast cancerprotactargeted protein degradationvepdegestrant
《Cancer Innovation》 2026 (3)
P.23-25,3
National Natural Science Foundation of China,Grant/Award Numbers:82125034,82330115National Key R&D Program of China,Grant/Award Numbers:2021YFA1300200,2021YFA1302100Beijing Outstanding Young Scientist Program,Grant/Award Number:JWZQ20240101007Beijing Frontier Research Center for Biological Structure。
评论